Is HCWB or GOSS more profitable?

HCW Biologics has a net margin of -34.73% compared to Gossamer Bio's net margin of -324.82%. Gossamer Bio's return on equity of 0.00% beat HCW Biologics' return on equity. Company Net Margins Return on Equity Return on Assets HCW Biologics -34.73% -486.87% -29.19% Gossamer Bio -324.82% N/A -96.10%

Do analysts rate HCWB or MIRA?

HCW Biologics currently has a consensus price target of $5.00, suggesting a potential upside of 278.79%. Given HCW Biologics' higher probable upside, analysts plainly believe HCW Biologics is more favorable than MIRA Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HCW Biologics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, HCWB or ELUT?

Elutia has higher revenue and earnings than HCW Biologics. HCW Biologics is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HCW Biologics $50K 189.02 -$7.96M -$9.46 N/A Elutia $12.46M 3.29 $53.38M $0.86 1.11

Is HCWB or ELUT more profitable?

Elutia has a net margin of 312.09% compared to HCW Biologics' net margin of -34.73%. Elutia's return on equity of 0.00% beat HCW Biologics' return on equity. Company Net Margins Return on Equity Return on Assets HCW Biologics -34.73% -486.87% -29.19% Elutia 312.09% N/A -53.97%

Is KALA or HCWB more profitable?

KALA BIO has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. HCW Biologics' return on equity of -486.87% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets KALA BIO N/A -1,336.10% -94.85% HCW Biologics -34.73% -486.87% -29.19%

HCW Biologics (HCWB) Competitors

$1.32 +0.11 (+9.09%)

Closing price 04:00 PM Eastern

Extended Trading

$1.28 -0.04 (-2.73%)

As of 07:59 PM Eastern

Compare

HCWB vs. GOSS, ACTU, MIRA, ELUT, and KALA

Should you buy HCW Biologics stock or one of its competitors? MarketBeat compares HCW Biologics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with HCW Biologics include Gossamer Bio (GOSS), Actuate Therapeutics (ACTU), MIRA Pharmaceuticals (MIRA), Elutia (ELUT), and KALA BIO (KALA). These companies are all part of the "pharmaceutical products" industry.

How does HCW Biologics compare to Gossamer Bio?

HCW Biologics (NASDAQ:HCWB) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

HCW Biologics has a beta of 2.21, suggesting that its share price is 121% more volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2, suggesting that its share price is 100% more volatile than the broader market.

HCW Biologics has a net margin of -34.73% compared to Gossamer Bio's net margin of -324.82%. Gossamer Bio's return on equity of 0.00% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-34.73%	-486.87%	-29.19%
Gossamer Bio	-324.82%	N/A	-96.10%

HCW Biologics currently has a consensus target price of $5.00, suggesting a potential upside of 278.79%. Gossamer Bio has a consensus target price of $5.00, suggesting a potential upside of 2,718.49%. Given Gossamer Bio's stronger consensus rating and higher possible upside, analysts clearly believe Gossamer Bio is more favorable than HCW Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

HCW Biologics has higher earnings, but lower revenue than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$50K	189.02	-$7.96M	-$9.46	N/A
Gossamer Bio	$55.54M	0.75	-$170.37M	-$0.79	N/A

3.0% of HCW Biologics shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 9.1% of HCW Biologics shares are owned by company insiders. Comparatively, 7.2% of Gossamer Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, HCW Biologics had 1 more articles in the media than Gossamer Bio. MarketBeat recorded 2 mentions for HCW Biologics and 1 mentions for Gossamer Bio. Gossamer Bio's average media sentiment score of 1.55 beat HCW Biologics' score of 1.44 indicating that Gossamer Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
HCW Biologics	Positive
Gossamer Bio	Very Positive

Summary

HCW Biologics and Gossamer Bio tied by winning 8 of the 16 factors compared between the two stocks.

How does HCW Biologics compare to Actuate Therapeutics?

Actuate Therapeutics (NASDAQ:ACTU) and HCW Biologics (NASDAQ:HCWB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

Actuate Therapeutics presently has a consensus target price of $17.50, suggesting a potential upside of 779.40%. HCW Biologics has a consensus target price of $5.00, suggesting a potential upside of 278.79%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Actuate Therapeutics is more favorable than HCW Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Actuate Therapeutics has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. Actuate Therapeutics' return on equity of -430.93% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-430.93%	-180.86%
HCW Biologics	-34.73%	-486.87%	-29.19%

3.0% of HCW Biologics shares are held by institutional investors. 58.0% of Actuate Therapeutics shares are held by insiders. Comparatively, 9.1% of HCW Biologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Actuate Therapeutics has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, HCW Biologics has a beta of 2.21, suggesting that its stock price is 121% more volatile than the broader market.

HCW Biologics has higher revenue and earnings than Actuate Therapeutics. Actuate Therapeutics is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A
HCW Biologics	$50K	189.02	-$7.96M	-$9.46	N/A

In the previous week, Actuate Therapeutics had 1 more articles in the media than HCW Biologics. MarketBeat recorded 3 mentions for Actuate Therapeutics and 2 mentions for HCW Biologics. HCW Biologics' average media sentiment score of 1.44 beat Actuate Therapeutics' score of 0.62 indicating that HCW Biologics is being referred to more favorably in the news media.

Company	Overall Sentiment
Actuate Therapeutics	Positive
HCW Biologics	Positive

Summary

Actuate Therapeutics beats HCW Biologics on 8 of the 15 factors compared between the two stocks.

How does HCW Biologics compare to MIRA Pharmaceuticals?

HCW Biologics (NASDAQ:HCWB) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

3.0% of HCW Biologics shares are held by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 9.1% of HCW Biologics shares are held by insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

HCW Biologics has higher revenue and earnings than MIRA Pharmaceuticals. MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$50K	189.02	-$7.96M	-$9.46	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A

In the previous week, HCW Biologics and HCW Biologics both had 2 articles in the media. HCW Biologics' average media sentiment score of 1.44 beat MIRA Pharmaceuticals' score of 0.47 indicating that HCW Biologics is being referred to more favorably in the media.

Company	Overall Sentiment
HCW Biologics	Positive
MIRA Pharmaceuticals	Neutral

HCW Biologics has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market.

HCW Biologics currently has a consensus price target of $5.00, suggesting a potential upside of 278.79%. Given HCW Biologics' higher probable upside, analysts plainly believe HCW Biologics is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

MIRA Pharmaceuticals has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. MIRA Pharmaceuticals' return on equity of -140.82% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-34.73%	-486.87%	-29.19%
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%

Summary

HCW Biologics beats MIRA Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does HCW Biologics compare to Elutia?

HCW Biologics (NASDAQ:HCWB) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

HCW Biologics has a beta of 2.21, suggesting that its stock price is 121% more volatile than the broader market. Comparatively, Elutia has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market.

Elutia has a net margin of 312.09% compared to HCW Biologics' net margin of -34.73%. Elutia's return on equity of 0.00% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-34.73%	-486.87%	-29.19%
Elutia	312.09%	N/A	-53.97%

HCW Biologics presently has a consensus target price of $5.00, suggesting a potential upside of 278.79%. Elutia has a consensus target price of $6.00, suggesting a potential upside of 527.22%. Given Elutia's stronger consensus rating and higher possible upside, analysts clearly believe Elutia is more favorable than HCW Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Elutia has higher revenue and earnings than HCW Biologics. HCW Biologics is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$50K	189.02	-$7.96M	-$9.46	N/A
Elutia	$12.46M	3.29	$53.38M	$0.86	1.11

In the previous week, Elutia had 2 more articles in the media than HCW Biologics. MarketBeat recorded 4 mentions for Elutia and 2 mentions for HCW Biologics. HCW Biologics' average media sentiment score of 1.44 beat Elutia's score of 0.96 indicating that HCW Biologics is being referred to more favorably in the media.

Company	Overall Sentiment
HCW Biologics	Positive
Elutia	Positive

3.0% of HCW Biologics shares are held by institutional investors. Comparatively, 74.0% of Elutia shares are held by institutional investors. 9.1% of HCW Biologics shares are held by company insiders. Comparatively, 27.6% of Elutia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Elutia beats HCW Biologics on 11 of the 15 factors compared between the two stocks.

How does HCW Biologics compare to KALA BIO?

KALA BIO (NASDAQ:KALA) and HCW Biologics (NASDAQ:HCWB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

KALA BIO currently has a consensus price target of $1,018.75, indicating a potential upside of 41,144.94%. HCW Biologics has a consensus price target of $5.00, indicating a potential upside of 278.79%. Given KALA BIO's higher probable upside, equities analysts clearly believe KALA BIO is more favorable than HCW Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

KALA BIO has a beta of -2.4, meaning that its share price is 340% less volatile than the broader market. Comparatively, HCW Biologics has a beta of 2.21, meaning that its share price is 121% more volatile than the broader market.

HCW Biologics has higher revenue and earnings than KALA BIO. HCW Biologics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A
HCW Biologics	$50K	189.02	-$7.96M	-$9.46	N/A

KALA BIO has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. HCW Biologics' return on equity of -486.87% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KALA BIO	N/A	-1,336.10%	-94.85%
HCW Biologics	-34.73%	-486.87%	-29.19%

24.6% of KALA BIO shares are owned by institutional investors. Comparatively, 3.0% of HCW Biologics shares are owned by institutional investors. 2.2% of KALA BIO shares are owned by company insiders. Comparatively, 9.1% of HCW Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, KALA BIO and KALA BIO both had 2 articles in the media. HCW Biologics' average media sentiment score of 1.44 beat KALA BIO's score of 0.44 indicating that HCW Biologics is being referred to more favorably in the news media.

Company	Overall Sentiment
KALA BIO	Neutral
HCW Biologics	Positive

Summary

HCW Biologics beats KALA BIO on 8 of the 12 factors compared between the two stocks.

Get HCW Biologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HCWB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HCWB vs. The Competition

Export

Metric	HCW Biologics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.45M	$3.38B	$6.51B	$11.99B
Dividend Yield	N/A	2.33%	2.67%	5.62%
P/E Ratio	-0.14	19.79	24.24	24.11
Price / Sales	189.02	172.08	473.84	84.01
Price / Cash	N/A	120.20	43.05	54.72
Price / Book	1.57	8.21	10.49	6.82
Net Income	-$7.96M	$23.89M	$3.56B	$337.52M
7 Day Performance	-19.02%	-3.00%	-2.02%	-0.96%
1 Month Performance	328.02%	-1.64%	0.66%	1.68%
1 Year Performance	-74.71%	40.20%	21.85%	26.88%

HCW Biologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HCWB HCW Biologics	3.8933 of 5 stars	$1.32 +9.1%	$5.00 +278.8%	-78.0%	$9.45M	$50K	N/A	40	Positive News Short Interest Decrease
GOSS Gossamer Bio	2.7926 of 5 stars	$0.19 -5.9%	$5.00 +2,555.3%	-87.5%	$44.19M	$48.47M	N/A	180	Positive News
ACTU Actuate Therapeutics	2.211 of 5 stars	$1.82 -3.2%	$17.50 +861.5%	-77.3%	$43.55M	N/A	N/A	10	Positive News Analyst Forecast
MIRA MIRA Pharmaceuticals	1.0448 of 5 stars	$1.01 -2.9%	N/A	-21.6%	$42.44M	N/A	N/A	2
ELUT Elutia	4.0538 of 5 stars	$0.99 -4.8%	$6.00 +506.0%	-47.7%	$42.36M	$12.29M	1.15	180	News Coverage Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HCWB) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HCW Biologics (HCWB) Competitors

HCWB vs. GOSS, ACTU, MIRA, ELUT, and KALA

How does HCW Biologics compare to Gossamer Bio?

Summary

How does HCW Biologics compare to Actuate Therapeutics?

Summary

How does HCW Biologics compare to MIRA Pharmaceuticals?

Summary

How does HCW Biologics compare to Elutia?

Summary

How does HCW Biologics compare to KALA BIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCWB vs. The Competition

HCW Biologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HCW Biologics (HCWB) Competitors

HCWB vs. GOSS, ACTU, MIRA, ELUT, and KALA

How does HCW Biologics compare to Gossamer Bio?

Which has more volatility & risk, HCWB or GOSS?

Is HCWB or GOSS more profitable?

Do analysts prefer HCWB or GOSS?

Which has preferable earnings & valuation, HCWB or GOSS?

Do insiders and institutionals hold more shares of HCWB or GOSS?

Does the media favor HCWB or GOSS?

Summary

How does HCW Biologics compare to Actuate Therapeutics?

Do analysts recommend ACTU or HCWB?

Is ACTU or HCWB more profitable?

Do insiders & institutionals hold more shares of ACTU or HCWB?

Which has more volatility & risk, ACTU or HCWB?

Which has higher earnings & valuation, ACTU or HCWB?

Does the media prefer ACTU or HCWB?

Summary

How does HCW Biologics compare to MIRA Pharmaceuticals?

Do institutionals & insiders have more ownership in HCWB or MIRA?

Which has better earnings and valuation, HCWB or MIRA?

Does the media favor HCWB or MIRA?

Which has more volatility & risk, HCWB or MIRA?

Do analysts rate HCWB or MIRA?

Is HCWB or MIRA more profitable?

Summary

How does HCW Biologics compare to Elutia?

Which has more risk and volatility, HCWB or ELUT?

Is HCWB or ELUT more profitable?

Do analysts rate HCWB or ELUT?

Which has higher valuation and earnings, HCWB or ELUT?

Does the media favor HCWB or ELUT?

Do insiders & institutionals have more ownership in HCWB or ELUT?

Summary

How does HCW Biologics compare to KALA BIO?

Do analysts rate KALA or HCWB?

Which has more volatility & risk, KALA or HCWB?

Which has higher valuation & earnings, KALA or HCWB?

Is KALA or HCWB more profitable?

Do insiders & institutionals believe in KALA or HCWB?

Does the media prefer KALA or HCWB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCWB vs. The Competition

HCW Biologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools